Oscar Health, Inc. (NYSE:OSCR) COO Sells $354,006.40 in Stock

Oscar Health, Inc. (NYSE:OSCR) COO Steven Wolin sold 19,580 shares of Oscar Health stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $18.08, for a total transaction of $354,006.40. Following the sale, the chief operating officer now owns 102,598 shares of the company’s stock, valued at approximately $1,854,971.84. The trade was a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Oscar Health Price Performance

NYSE:OSCR opened at $17.99 on Wednesday. Oscar Health, Inc. has a 12-month low of $7.50 and a 12-month high of $23.79. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of -299.78 and a beta of 1.63. The company’s 50-day moving average is $17.25 and its two-hundred day moving average is $17.97. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The firm had revenue of $2.42 billion for the quarter, compared to analysts’ expectations of $2.33 billion. Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The business’s quarterly revenue was up 68.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) EPS. Research analysts expect that Oscar Health, Inc. will post -0.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on OSCR. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a research note on Tuesday, September 10th. Bank of America cut Oscar Health from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $21.00 to $13.50 in a research report on Wednesday, November 6th. Finally, UBS Group initiated coverage on shares of Oscar Health in a research note on Monday, October 7th. They issued a “neutral” rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.93.

Institutional Investors Weigh In On Oscar Health

Hedge funds have recently made changes to their positions in the business. Point72 Hong Kong Ltd purchased a new position in Oscar Health during the second quarter worth about $78,000. Quest Partners LLC purchased a new position in shares of Oscar Health during the 2nd quarter worth about $93,000. KBC Group NV boosted its position in shares of Oscar Health by 41.2% in the third quarter. KBC Group NV now owns 4,552 shares of the company’s stock worth $97,000 after acquiring an additional 1,328 shares during the last quarter. Amalgamated Bank grew its holdings in Oscar Health by 27.7% in the second quarter. Amalgamated Bank now owns 6,727 shares of the company’s stock valued at $106,000 after purchasing an additional 1,458 shares during the period. Finally, Optimum Investment Advisors acquired a new position in Oscar Health during the third quarter worth approximately $142,000. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.